53B31ABD-AD68-4A44-A525-23FD413115D5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.533508541392904
- age_years
- 78
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.635
- ALLOGRAFT_REJECTION+0.614
- INTERFERON_ALPHA_RESPONSE+0.608
- TNFA_SIGNALING_VIA_NFKB+0.598
- IL6_JAK_STAT3_SIGNALING+0.597
- ANGIOGENESIS+0.596
- INFLAMMATORY_RESPONSE+0.569
- MYC_TARGETS_V1+0.557
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.556
- OXIDATIVE_PHOSPHORYLATION+0.510
Top 10 suppressed
- KRAS_SIGNALING_DN-0.385
- SPERMATOGENESIS-0.290
- HEDGEHOG_SIGNALING-0.250
- MYOGENESIS-0.124
- MITOTIC_SPINDLE-0.122
- PANCREAS_BETA_CELLS-0.064
- ESTROGEN_RESPONSE_EARLY-0.009
- UV_RESPONSE_DN+0.037
- WNT_BETA_CATENIN_SIGNALING+0.040
- APICAL_JUNCTION+0.074
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.985 |
| 2 | 9BB56866-4E99-4E8A-A63F-2D4801558F14 | — | — | 0.984 |
| 3 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.982 |
| 4 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.981 |
| 5 | 5307FA7F-DFE5-42BC-BFC7-826AACAAE799 | — | — | 0.979 |
| 6 | B7A23896-4182-48D3-A1D9-92C781BF283F | — | — | 0.975 |
| 7 | 3027792F-79B6-4729-9452-C4A72A7C4686 | — | — | 0.975 |
| 8 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.973 |
| 9 | D06FFD0C-80D4-413D-9C83-62D9C163EDAB | — | — | 0.972 |
| 10 | D8A3D7E7-BDC0-42FF-B451-E25F472E8612 | — | — | 0.971 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.635 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.614 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.608 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.598 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.597 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.596 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.569 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.557 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.556 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.504 | Inavolisib | — uncovered |
| APOPTOSIS | 0.495 | Idelalisib | — uncovered |
| COMPLEMENT | 0.492 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.488 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.461 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.458 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.453 | Idelalisib | — uncovered |
| HYPOXIA | 0.430 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.428 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.425 | Idelalisib | — uncovered |